CFS Investment Advisory Services’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$399K Sell
16,411
-4,787
-23% -$125K 0.03% 280
2026
Q1
$584K Buy
21,198
+492
+2% +$13.1K 0.04% 238
2025
Q4
$516K Sell
20,706
-2,673
-11% -$67.4K 0.04% 235
2025
Q3
$579K Buy
23,379
+63
+0.3% +$1.55K 0.04% 226
2025
Q2
$565K Sell
23,316
-233
-1% -$5.43K 0.05% 219
2025
Q1
$597K Buy
23,549
+829
+4% +$21.7K 0.05% 204
2024
Q4
$603K Sell
22,720
-1,329
-6% -$36K 0.05% 196
2024
Q3
$696K Sell
24,049
-24,319
-50% -$709K 0.06% 182
2024
Q2
$1.35M Buy
+48,368
New +$1.33M 0.11% 116
2023
Q3
Sell
-55,480
Closed -$2.04M 226
2023
Q2
$2.04M Buy
+55,480
New +$2.16M 0.26% 74
2022
Q3
Sell
-22,786
Closed -$1.2M 329
2022
Q2
$1.2M Sell
22,786
-1,127,478
-98% -$57.5M 0.18% 115
2022
Q1
$22K Buy
1,150,264
+1,127,693
+4,996% +$58.5M 0.1% 103
2021
Q4
$1.19M Buy
22,571
+990
+5% +$49.1K 0.16% 128
2021
Q3
$928K Buy
+21,581
New +$956K 0.13% 140
2020
Q4
$670K Buy
+18,198
New +$668K 0.11% 134

Other funds holding PFE

CFS Investment Advisory Services's PFE Position: Q2 2026 in Review

CFS Investment Advisory Services reduced its Pfizer (PFE) stake by 23% in Q2 2026, selling an estimated $125K and leaving 16,411 shares worth $399K. The position accounts for 0.03% of the portfolio, ranked #280.

CFS Investment Advisory Services first reported a position in PFE in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.04M in Q2 2023. 799 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • CFS Investment Advisory Services held 16,411 shares of Pfizer worth $399K as of Q2 2026.
  • CFS Investment Advisory Services sold 4,787 Pfizer shares in Q2 2026, an estimated $125K.
  • Pfizer made up 0.03% of CFS Investment Advisory Services's portfolio in Q2 2026, its #280 holding.
  • CFS Investment Advisory Services first reported a position in Pfizer in Q4 2020 and has held it in 15 quarters since.
  • CFS Investment Advisory Services's Pfizer position peaked at $2.04M in Q2 2023.
  • 799 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on CFS Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.